Ilumetri (Tildrakizumab)

Tildrakizumab is a monoclonal antibody that binds specifically to the p19 subunit of interleukin‑23. By blocking IL‑23 from activating its receptor, the drug interrupts the downstream inflammatory cascade that drives the formation of psoriatic plaques.

The dosing regimen for Ilumetri is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and treatment response. The prescriber will decide the appropriate dose and administration schedule.

Safety data for tildrakizumab in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Ilumetri product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Ilumetri belongs to the IL‑23 inhibitor class, offering a targeted mechanism distinct from TNF‑α or IL‑17 inhibitors. Compared with some alternatives, it may have a favorable dosing interval and a safety profile focused on fewer systemic infections, but individual response varies and should be evaluated by the treating physician.

Ilumetri must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours.

Ilumetri is given by subcutaneous injection, typically in the thigh, abdomen, or upper arm. The injection is performed by a healthcare professional or a trained patient following the prescriber’s instructions and using aseptic technique.

Serious risks include severe allergic reactions, opportunistic infections, new or worsening inflammatory bowel disease, hepatic abnormalities, and rare reports of malignancies. Patients should be monitored regularly for signs of infection, liver dysfunction, or unexpected skin changes.

Ilumetri is contraindicated in patients with known hypersensitivity to tildrakizumab or any excipients. It should be avoided in individuals with active serious infections, uncontrolled tuberculosis, or those receiving live vaccines. Caution is also advised for pregnant or nursing women and patients with a history of malignancy.